Huiqian Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huiqian Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Cheng Zhao
Shanghai TCM-Integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
1 shared publication- Wenmin Dong
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
1 shared publication - YanCheng Dai
Shanghai TCM-Integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
1 shared publication - Yi Zhou
Shanghai TCM-Integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
1 shared publication - Ying Chen
Shanghai TCM-Integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
1 shared publication - Yiyuan Cao
Shanghai TCM-Integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
circRNA circFAT1(e2) Elevates the Development of Non‐Small‐Cell Lung Cancer by Regulating miR‐30e‐5p and USP22
Background. As a newly discovered regulatory RNA, circular RNA (circRNA) has become a hot spot in many tumor pieces of research. In recent years, it has been discovered that circRNAs have multiple biological effects in different stages of cancer. However, the expression pattern and mechanism of circFAT1(e2) in non‐small‐cell lung cancer (NSCLC) are still unclear. Methods. The expressions of circFAT1(e2) in NSCLC tissues and cell lines were studied. Functionally, CCK‐8 and transwell experiments were performed in A549 and H1299. In addition, we also performed a dual‐luciferase report analysis to clarify the mechanism of action of circFAT1(e2). Results. circFAT1(e2) was significantly upregulated in NSCLC tissues and cell lines. circFAT1(e2) gene knockdown could significantly inhibit the proliferation, migration, and invasion of NSCLC cells. Loss of function testing found that circFAT1(e2) functioned as an oncogene in NSCLC cells. In addition, circFAT1(e2) acted as a ceRNA to spongy miR‐30e‐5p, which led to the increase in USP22 and promoted cell growth. Conclusions. The circFAT1(e2)‐miR‐30e‐5p‐USP22 axis is a crucial part of the progression of NSCLC. This study suggests that circFAT1(e2) may be an important potential of prognostic prediction and treatment targets for NSCLC patients.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccesscircRNA circFAT1(e2) Elevates the Development of Non‐Small‐Cell Lung Cancer by Regulating miR‐30e‐5p and USP22
Background. As a newly discovered regulatory RNA, circular RNA (circRNA) has become a hot spot in many tumor pieces of research. In recent years, it has been discovered that circRNAs have multiple biological effects in different stages of cancer. However, the expression pattern and mechanism of circFAT1(e2) in non‐small‐cell lung cancer (NSCLC) are still unclear. Methods. The expressions of circFAT1(e2) in NSCLC tissues and cell lines were studied. Functionally, CCK‐8 and transwell experiments were performed in A549 and H1299. In addition, we also performed a dual‐luciferase report analysis to clarify the mechanism of action of circFAT1(e2). Results. circFAT1(e2) was significantly upregulated in NSCLC tissues and cell lines. circFAT1(e2) gene knockdown could significantly inhibit the proliferation, migration, and invasion of NSCLC cells. Loss of function testing found that circFAT1(e2) functioned as an oncogene in NSCLC cells. In addition, circFAT1(e2) acted as a ceRNA to spongy miR‐30e‐5p, which led to the increase in USP22 and promoted cell growth. Conclusions. The circFAT1(e2)‐miR‐30e‐5p‐USP22 axis is a crucial part of the progression of NSCLC. This study suggests that circFAT1(e2) may be an important potential of prognostic prediction and treatment targets for NSCLC patients.